Inhibition of glutaminase, a key enzyme in the conversion of glutamine to glutamate, by BPTES [bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide] and CB-839 has been shown to have anti-proliferative effect in triple negative breast cancer, leukemia and glioma [28–30]. This evidence concerns the gene GLS and triple-negative breast carcinoma.